-411.97
80,334.81
-0.51%
Market Closed
1,404.85
-0.08%
-18.35
1,926.3
-0.94%
2.25
3,447.45
0.07%
1,866
-1.58%
1,426.7
-0.6%
-7.4
768.75
-0.95%
1,511.25
0.18%
8,818
-1.86%
2,355.25
-0.62%
-0.3
430.35
-0.07%
781.2
-0.55%
3,320.6
-0.05%
1,766.2
-0.85%
1,579.1
1.05%
2,112.3
0.81%
12,371.4
-2.04%
3,030.8
-2.85%
1,171.2
0.8%
11,629.3
-0.23%
-2.45
339.75
-0.72%
2,005.65
-1.14%
-5.6
233.1
-2.35%
4,419.45
-1.13%
3,363.45
0.69%
307.85
-1.09%
1,330.05
-0.62%
2,285.5
-2.97%
3,972.65
-0.68%
-2.8
241.25
-1.15%
681.9
0.21%
385.2
0.36%
-15.95
950
-1.65%
-7.45
229.45
-3.14%
306.8
-1.05%
-7.85
2,329
-0.34%
2,302.5
-1.29%
-150.35
7,696.45
-1.92%
520.05
-2.3%
5,145.1
-2.76%
140.6
-2.7%
-31.5
5,195
-0.6%
2,700.25
0.09%
143.65
-1.81%
409.2
-3.18%
1,720
-1.39%
488.85
-4.58%
-24.45
655.25
-3.6%
-219.35
5,925
-3.57%
251.25
-1.91%
407.05
-2.14%
-411.97
80334.81
-0.51%
Market Closed

CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

AstraZeneca India gets DCGI permission for leukaemia drug
DSIJ Intelligence
/ Categories: Trending, DSIJ News

AstraZeneca India gets DCGI permission for leukaemia drug

AstraZeneca Pharma India Limited announced that it has received import and marketing permission in form CT-20 from Drugs Controller General of India (DCGI) for Acalabrutinib 100 mg capsules (Calquence).

As a result, the receipt of this import and market permission has paved way for the launch of the company's Acalabrutinib 100 mg capsules (Calquence) in India, subject to related statutory approvals and licences. The drug indicated is used for the treatment of patients with Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Lymphoma (SLL).

AstraZeneca Pharma India Limited is a global biopharmaceutical company engaged in the discovery, development and commercialisation of medicines for core areas of healthcare, including cardiovascular disease, cancer and respiratory, inflammatory and autoimmune disease.

At 12.30 pm on Friday, the stock was trading at Rs 2,287.40, up by 1.39 per cent or Rs 31.25 per share. The 52-week high is recorded at Rs 2,940.45 and the 52-week low is Rs 1,635.30 on BSE.

Previous Article Wipro to co-develop solutions with SAP for retail & fashion
Next Article Man Industries announce 20 per cent interim dividend
Print
1130 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR